Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: Results of a phase I trial

Journal of Clinical Oncology

Volumn 20, Issue 18, 2002, Pages 3815-3825

  Herbst, Roy S ^a   Maddox, Anne Marie ^a   Rothenberg, Mace L ^a   Small, Eric J ^a   Rubin, Eric H ^a   Baselga, Jose ^a   Rojo, Federico ^a   Hong, Waun Ki ^a   Swaisland, Helen ^a   Averbuch, Steven D ^a   Ochs, Judith ^a   LoRusso, Patricia Mucci ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ACNE; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; CANCER GRADING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DOSE CALCULATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG EXPOSURE; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERANCE; FEMALE; HEAD AND NECK CANCER; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RASH; SOLID TUMOR; STEADY STATE; TOXICITY;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FEMALE; GASTROINTESTINAL DISEASES; HEAD AND NECK NEOPLASMS; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; PROTEIN-TYROSINE KINASES; QUINAZOLINES; SKIN DISEASES;

EID: 0037106377     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.03.038     Document Type: Article

References (46)

1. Molecules in focus: EGF receptor
2. Growth factors and cancer
3. Epidermal growth factor-related peptides and their receptors in human malignancies
4. The epidermal growth factor receptor and its inhibition in cancer
5. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung
6. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: Amphiregulin and microvessel count are independent prognostic indicators of survival
7. Evidence for a role of EGF receptor in the progression of human lung carcinoma
8. Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas
9. The epidermal growth factor receptor (EGFR): A new target in cancer therapy
10. Epidermal growth factor and laminin receptors contribute to migratory and invasive properties of gliomas
11. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt
12. The epidermal growth factor receptor in breast cancer
13. Correlation of cisplatin sensitivity with differential alteration of EGFR expression in head and neck cancer cells
14. Endocrine resistance in breast cancer can involve a switch towards EGFR signaling pathways and a gain of sensitivity to an EGFR-selective tyrosine kinase inhibitor, ZD1839
15. Reduced growth rate accompanied by aberrant epidermal growth factor signaling in drug resistant human breast cancer cells
16. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas
17. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials
18. Objective regressions in non-small cell lung cancer patients treated in phase I trials of ZD1839 ('Iressa'), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR)
19. Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD 1839 in healthy volunteers
20. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition
21. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: Results of a phase I trial
22. The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival
23. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p 53 overexpression
24. A biological staging model for operable non-small cell lung cancer
25. Molecular biologic substaging of stage I lung cancer according to gender and histology
26. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival
27. Potential molecular prognostic markers in head and neck squamous cell carcinomas
28. Final results of a phase I intermittent dose-escalation trial of ZD1839 ('Iressa') in Japanese patients with various solid tumours
29. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
30. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase
31. ZD1839 ('Iressa') a selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI): Inhibition of c-fos mRNA, an intermediate marker of EGFR activation, correlates with tumor growth inhibition
32. Clinical trial designs for cytostatic agents: Are new approaches needed?
33. The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure
34. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument
35. The performance status scale for head and neck cancer patients and the functional assessment of cancer therapy-head and neck scale: A study of utility and validity
36. What is a clinically meaningful change (CMC) on the Functional Assessment of Cancer Therapy-Lung (FACT-L): Analysis of ECOG 5592 data
37. Monoclonal antibodies directed at growth factor receptors
38. Growth factors and their receptors: New targets for prostate cancer therapy
39. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies
40. Phase I dose escalation study of epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor CP-358,774 in patients with advanced solid tumors
41. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer
42. ZD 1839, an epidermal growth factor tyrosine kinase inhibitor selected for clinical development
43. A pilot trial demonstrates the safety of ZD1839 ('Iressa'), an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with carboplatin (C) and paclitaxel (P) in previously untreated advanced non-small cell lung cancer (NSCLC)
44. Final results from a phase II trial of ZD1839 ('Iressa') for patients with advanced non-small-cell lung cancer (IDEAL 1)
45. A phase II trial of ZD1839 ('Iressa') in advanced non-small-cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2)